Related Experiment Videos
Guidelines for management of patients with chronic heart failure in Australia
H Krum1,
1Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, VIC. henry.krum@med.monash.edu.au
Insights
Chronic heart failure (CHF) is common in older adults, with management focusing on non-pharmacological and pharmacological therapies like ACE inhibitors and beta-blockers to improve survival and symptoms.
Area of Science:
- Cardiology
- Geriatrics
- Internal Medicine
Background:
- Chronic heart failure (CHF) prevalence significantly increases with age, affecting 1% of individuals aged 50-59 and becoming a leading cause of hospitalization in the elderly.
- Key etiologies of CHF include ischemic heart disease, hypertension, and idiopathic dilated cardiomyopathy.
- Diagnosis relies on clinical presentation and objective assessments like echocardiography to evaluate ventricular function.
Purpose of the Study:
- To outline the diagnostic criteria for chronic heart failure.
- To detail current management strategies aimed at preventing disease progression, alleviating symptoms, and enhancing survival.
- To review both non-pharmacological and pharmacological treatment options for CHF.
Main Methods:
- Review of established diagnostic indicators for chronic heart failure.
- Analysis of non-pharmacological interventions such as exercise, home support, and risk factor modification.
- Evaluation of pharmacological treatments including Angiotensin-Converting Enzyme (ACE) inhibitors, beta-blockers, diuretics, spironolactone, angiotensin II receptor antagonists, and digoxin.
- Consideration of surgical interventions for select patients.
Main Results:
- Non-pharmacological approaches support CHF management through lifestyle adjustments and risk reduction.
- ACE inhibitors are foundational for CHF pharmacotherapy, crucial for disease modification and survival.
- Beta-blockers enhance survival when combined with ACE inhibitors in symptomatic patients.
- Diuretics effectively manage symptoms and fluid balance.
- Other agents like spironolactone, ARBs, and digoxin offer adjunctive benefits in specific cases.
- Surgical options provide therapeutic avenues for highly selected CHF populations.
Conclusions:
- Effective chronic heart failure management integrates non-pharmacological, pharmacological, and, in select cases, surgical strategies.
- Early diagnosis and comprehensive treatment are vital for improving patient outcomes and quality of life.
- Continued research into novel therapeutic approaches is essential for advancing CHF care.
Abstract:
Chronic heart failure (CHF) affects approximately 1% of people aged 50-59 years, and this high prevalence increases dramatically with age. CHF is a common reason for hospital admission and general practitioner consultation in the elderly. Common causes of CHF are ischaemic heart disease, hypertension and idiopathic dilated cardiomyopathy. Diagnosis of CHF is based on clinical features and objective measurement of ventricular function (eg, echocardiography). Management is directed at prevention, retarding disease progression, relief of symptoms and prolonging survival. Non-pharmacological approaches include exercise, home-based support and risk-factor modification. Angiotensin-converting enzyme (ACE) inhibitors are the cornerstone of pharmacological therapy to prevent disease progression and prolong survival. beta-Blockers prolong survival when added to ACE inhibitors in symptomatic patients. Diuretics provide symptom relief and restoration or maintenance of euvolaemia. Spironolactone, angiotensin II receptor antagonists and digoxin may be useful in some patients. Surgical approaches in highly selected patients may include myocardial revascularisation, insertion of devices and cardiac transplantation.